个性化文献订阅>期刊> Journal of clinical investigation
 

A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease

  作者 Deane, R; Singh, I; Sagare, AP; Bell, RD; Ross, NT; LaRue, B; Love, R; Perry, S; Paquette, N; Deane, RJ; Thiyagarajan, M; Zarcone, T; Fritz, G; Friedman, AE; Miller, BL; Zlokovic, BV  
  选自 期刊  Journal of clinical investigation;  卷期  2012年122-4;  页码  1377-1392  
  关联知识点  
 

[摘要]In Alzheimer disease (AD), amyloid beta peptide (A beta) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates A beta-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked A beta binding to the V domain of RAGE and inhibited A beta 40- and A beta 42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APP(sw/0) mice overexpressing human A beta-precursor protein, a transgenic mouse model of AD with established A beta pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating A beta 40 and A beta 42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited beta-secretase activity and A beta production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced A beta 40 and A beta 42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APP(sw/0) mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of A beta-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.

 
      被申请数(1)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内